Companies › Kissei Pharmaceutical
3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 2; Oncology, Neurology, Genitourinary; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rovatirelin (KPS-0373) Thyrotropin-releasing hormone receptor agonist | TRHR | Phase 3 | Spinocerebellar Degeneration | Mar 2027 |
| Linzagolix (KLH-2109) Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Endometriosis | Nov 2027 |
| Olutasidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 2 | Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia | Sep 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07040137 | Rovatirelin (KPS-0373) | Phase 3 | Spinocerebellar Degeneration | Neurology | Mar 2027 |
| NCT07015268 | Linzagolix (KLH-2109) | Phase 3 | Endometriosis | Genitourinary | Nov 2027 |
| NCT07604064 | Olutasidenib | Phase 2 | Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia | Oncology | Sep 2030 |
Servier Eli Lilly Nuvation Bio Bristol-Myers Squibb Servier Affaires Médicales Hutchmed Rigel Pharmaceuticals Servier Bio-Innovation Novartis Daiichi Sankyo
Woolsey Pharmaceuticals Servier Italfarmaco Shanghai Jiaolian Drug Research and Development SK Life Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.